AbbVie recently received the Food and Drug Administration's new breakthrough designation for its interferon-free hepatitis C treatment regimen. Although the product is groundbreaking and likely a future blockbuster, Motley Fool health care analyst David Williamson cautions investors not to get too excited over this development.
Watch the video below and find out why despite the new breakthrough status, AbbVie may have trouble competing.
Follow David on Twitter: @MotleyDavid.
